Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...

As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

At close, the Sensex was down 501.51 points, or 0.61 per cent, at 81,757.73, and the Nifty was down 143.05 points, or 0.57 ...

Nifty rose above 25,100 and Sensex gained 76 points, recovering from earlier losses led by sectoral strength.Stock-Specific ...

Little surprise then that Citi was top of Dealogic’s Asia Pacific ex-Japan G3 DCM revenue league table in 2024, with $77 ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...